These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 18710891)

  • 1. Introduction to a mini-forum on "glyconutrients".
    McClain DA
    Glycobiology; 2008 Sep; 18(9):651. PubMed ID: 18710891
    [No Abstract]   [Full Text] [Related]  

  • 2. A "glyconutrient sham".
    Schnaar RL; Freeze HH
    Glycobiology; 2008 Sep; 18(9):652-7; discussion 658-63. PubMed ID: 17855741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dietary supplements: background for dialogue between the industry and the medical profession.
    Friede AI
    Food Drug Law J; 1998; 53(3):413-20. PubMed ID: 10346719
    [No Abstract]   [Full Text] [Related]  

  • 4. Public health. Toward evidence-based health claims for foods.
    Katan MB; de Roos NM
    Science; 2003 Jan; 299(5604):206-7. PubMed ID: 12522235
    [No Abstract]   [Full Text] [Related]  

  • 5. DSHEA provisions confine FDA's authority to issue regulations that concern allegedly adulterated dietary supplements.
    McNamara SH; Siegner AW; Phelps EP
    Food Drug Law J; 1999; 54(4):595-8. PubMed ID: 11824456
    [No Abstract]   [Full Text] [Related]  

  • 6. A survey of developments in food and drug law from July 1998 to November 1999.
    Littlefield N; Hada NR
    Food Drug Law J; 2000; 55(1):35-56. PubMed ID: 12296348
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA regulation of ingredients in dietary supplements after passage of the Dietary Supplement Health and Education Act of 1994: an update.
    McNamara SH
    Food Drug Law J; 1996; 51(2):313-8. PubMed ID: 11822323
    [No Abstract]   [Full Text] [Related]  

  • 8. Conflict of interest in industry-sponsored drug development.
    Emanuel EJ
    Clin Adv Hematol Oncol; 2007 Apr; 5(4):265-7. PubMed ID: 17607285
    [No Abstract]   [Full Text] [Related]  

  • 9. Pediatric Research Equity Act.
    J Natl Cancer Inst; 2004 Dec; 96(24):1810. PubMed ID: 15601636
    [No Abstract]   [Full Text] [Related]  

  • 10. Big Pharma's Commedia.
    Steele FR
    Cell; 2005 Dec; 123(6):971-3. PubMed ID: 16360023
    [No Abstract]   [Full Text] [Related]  

  • 11. New dietary ingredient notifications: a comprehensive review and strategies for avoiding FDA objections.
    Talati AR
    Food Drug Law J; 2007; 62(2):387-98. PubMed ID: 17632968
    [No Abstract]   [Full Text] [Related]  

  • 12. Little common ground seen in proposed U.S. laws vs. regulations on dietary supplements.
    Nutrition; 1993; 9(5):478. PubMed ID: 8286892
    [No Abstract]   [Full Text] [Related]  

  • 13. The FDA, medical foods, and patents.
    Czap A
    Altern Med Rev; 2002 Oct; 7(5):367-8. PubMed ID: 12410621
    [No Abstract]   [Full Text] [Related]  

  • 14. Legal requirements for "functional food" claims.
    Patrick Noonan W; Noonan C
    Toxicol Lett; 2004 Apr; 150(1):19-24. PubMed ID: 15068821
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA has substantial and sufficient authority to regulate dietary supplements.
    McNamara SH; Siegner AW
    Food Drug Law J; 2002; 57(1):15-24. PubMed ID: 12118477
    [No Abstract]   [Full Text] [Related]  

  • 16. Regulatory initiatives for dietary supplements.
    FDA Consum; 2005; 39(1):27. PubMed ID: 15803593
    [No Abstract]   [Full Text] [Related]  

  • 17. Nutraceuticals and functional foods regulations in the United States and around the world.
    Bagchi D
    Toxicology; 2006 Apr; 221(1):1-3. PubMed ID: 16487648
    [No Abstract]   [Full Text] [Related]  

  • 18. Current good manufacturing practice in manufacturing, packaging, labeling, or holding operations for dietary supplements. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Jun; 72(121):34751-958. PubMed ID: 17674484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA user fees and innovation.
    Somberg J
    Am J Ther; 2008; 15(2):97. PubMed ID: 18356626
    [No Abstract]   [Full Text] [Related]  

  • 20. Perception and process at the Food and Drug Administration: obligations and trade-offs in rules and guidances.
    Seiguer E; Smith JJ
    Food Drug Law J; 2005; 60(1):17-32. PubMed ID: 15940852
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.